Scientific Oracle
Drug discovery
Computational target, indication, mechanism, candidate, and validation-priority decisions using existing evidence and data.
Start here
Drug Target Prioritization: A Falsifier-First Framework
Supporting guides
- Drug Target Prioritization: A Falsifier-First Framework
Drug Target Prioritization becomes decision-useful when the team states which target deserves the next validation budget, not when it collects another undirected summary. Use human genetics, disease biology, expression, tractability, safety, competitive landscape, and translational evidence to compare mechanisms and run this early falsifier: remove the strongest evidence source and test whether the target remains top-ranked. Continue only if the ranking survives.
- Target Identification vs Target Validation in Drug Discovery
Before funding deeper validation, Target Identification vs Target Validation in Drug Discovery should resolve whether the program is still generating candidates or testing a specific target thesis. The minimum credible analysis compares distinct routes using candidate breadth, causal evidence, perturbation data, assay readiness, translational bridge, and validation ownership and attempts to state the result that would make the target lose against a named alternative. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- A Drug Target Scorecard That Exposes Its Assumptions
Treat A Drug Target Scorecard That Exposes Its Assumptions as a ranking problem rather than a request for certainty. Define the decision about how to compare targets without hiding subjective weights, assemble genetics, efficacy rationale, safety, druggability, biomarkers, competition, tissue context, and data quality, and test whether the preferred route still leads after you perform weight and leave-one-evidence-lane sensitivity analyses. The recommendation remains bounded by the evidence and accountable specialist validation.
- What Counts as Evidence for Drug Target Validation?
What Counts as Evidence for Drug Target Validation? can shorten the search only by eliminating weak directions early. Start with which evidence classes materially strengthen or weaken a target thesis; compare mechanisms against causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety; and try to break the ranking with this challenge: test whether orthogonal interventions produce the predicted disease-relevant change. A negative result is valuable when it prevents the wrong validation cycle.
- Indication Prioritization: Rank Opportunity Without Erasing Biology
For Indication Prioritization, speed comes from a precise decision and a fast falsifier. State which disease context best fits a target or mechanism, evaluate competing routes with disease biology, target expression, genetic evidence, unmet need, biomarkers, model relevance, and competition, and attempt to remove commercial criteria and see whether the biological ranking remains coherent, then reverse the test. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- How to Build a Mechanism-of-Action Hypothesis
For How to Build a Mechanism-of-Action Hypothesis, the bounded choice is which causal chain connects an intervention to a disease-relevant outcome. Compare at least three live alternatives using binding or perturbation, pathway response, temporal order, dose response, rescue, alternatives, and off-target effects, then run the cheapest ranking-reversal test: predict an orthogonal perturbation or rescue result before running it. The defensible output is pursue, reframe, or stop—not final validation.
- How to Triage Drug Targets Before Wet-Lab Validation
Use How to Triage Drug Targets Before Wet-Lab Validation to decide which targets should enter expensive experimental assessment first before the next expensive commitment. Build the comparison around public genetics, expression, pathway, essentiality, safety, tractability, and literature contradiction and ask what would overturn the preferred route; the earliest useful challenge is: test whether the shortlist survives independent datasets and alternate normalization choices. Stop at a provisional decision and preserve the remaining validation boundary.
- Public Data for Drug Target Prioritization: What It Can Really Support
The practical question behind Public Data for Drug Target Prioritization is which public evidence can reduce uncertainty before proprietary experiments. Rank credible alternatives with dataset design, tissue relevance, cohort size, provenance, processing, missingness, and licensing, expose the strongest counterargument, and challenge the leader by trying to reproduce the central association in an independent public source. A useful answer changes the next allocation decision without pretending computation is final proof.
- Go/No-Go Criteria for Early Drug Discovery
Go/No-Go Criteria for Early Drug Discovery becomes decision-useful when the team states whether a target or program should enter the next discovery stage, not when it collects another undirected summary. Use predeclared biological, technical, safety, differentiation, and feasibility thresholds to compare mechanisms and run this early falsifier: require the top load-bearing claim to reproduce under an orthogonal method. Continue only if the ranking survives.
- Preclinical Evidence Reproducibility Before the Next Investment
Before funding deeper validation, Preclinical Evidence Reproducibility Before the Next Investment should resolve which preclinical result must survive independent challenge. The minimum credible analysis compares distinct routes using protocol detail, randomization, blinding, model relevance, raw data, effect size, uncertainty, and replication and attempts to repeat the decisive analysis or experiment with an independent operator or dataset. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- Target Safety Prioritization From Existing Evidence
Treat Target Safety Prioritization From Existing Evidence as a ranking problem rather than a request for certainty. Define the decision about which safety liabilities should change target ranking before deeper work, assemble human genetics, tissue expression, paralogs, on-target phenotypes, liabilities, therapeutic window, and modality, and test whether the preferred route still leads after you search for evidence where reduced target function produces an unacceptable phenotype. The recommendation remains bounded by the evidence and accountable specialist validation.
- Target Druggability Assessment: Separate Tractability From Desirability
Target Druggability Assessment can shorten the search only by eliminating weak directions early. Start with whether a biologically attractive target has a plausible intervention route; compare mechanisms against structure, pockets, ligandability, modality access, selectivity, localization, and precedent; and try to break the ranking with this challenge: test whether the proposed modality can reach and selectively modulate the target in context. A negative result is valuable when it prevents the wrong validation cycle.
- Human Genetics in Drug Target Prioritization
For Human Genetics in Drug Target Prioritization, speed comes from a precise decision and a fast falsifier. State how much causal and safety weight human genetic evidence should receive, evaluate competing routes with variant-to-gene mapping, effect direction, phenotype, ancestry, pleiotropy, dosage, and replication, and attempt to test colocalization or fine-mapping assumptions with alternative models and data. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- Multi-Omics Target Prioritization Without Data-Layer Voting
For Multi-Omics Target Prioritization Without Data-Layer Voting, the bounded choice is which cross-omic pattern genuinely strengthens a target mechanism. Compare at least three live alternatives using genomics, transcriptomics, proteomics, epigenomics, tissue context, batch effects, and causal ordering, then run the cheapest ranking-reversal test: hold out one omic layer and test whether the mechanism and ranking survive. The defensible output is pursue, reframe, or stop—not final validation.
- Drug Repurposing Hypotheses: From Signal to Testable Mechanism
Use Drug Repurposing Hypotheses to decide which existing compound-disease pairing deserves mechanistic and validation review before the next expensive commitment. Build the comparison around known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence and ask what would overturn the preferred route; the earliest useful challenge is: predict a target- or pathway-specific response distinguishable from general associations. Stop at a provisional decision and preserve the remaining validation boundary.
- Candidate Prioritization in Drug Discovery Under Multiple Objectives
The practical question behind Candidate Prioritization in Drug Discovery Under Multiple Objectives is which candidate best balances potency, selectivity, exposure, safety, developability, and information value. Rank credible alternatives with assay comparability, uncertainty, property tradeoffs, mechanism, off-targets, and route feasibility, expose the strongest counterargument, and challenge the leader by trying to perturb weights and assay normalization to test ranking stability. A useful answer changes the next allocation decision without pretending computation is final proof.
- Assay Artifact Checks Before Believing a Discovery Signal
Assay Artifact Checks Before Believing a Discovery Signal becomes decision-useful when the team states whether an apparent activity signal could be technical rather than biological, not when it collects another undirected summary. Use controls, interference, aggregation, plate effects, readout specificity, concentration response, and orthogonal assays to compare mechanisms and run this early falsifier: repeat with an orthogonal readout and interference controls. Continue only if the ranking survives.
- Biomarker Hypothesis Prioritization From Existing Data
Before funding deeper validation, Biomarker Hypothesis Prioritization From Existing Data should resolve which biomarker candidate is sufficiently specific, reproducible, and decision-relevant to validate. The minimum credible analysis compares distinct routes using measurement reliability, disease context, temporal behavior, confounding, effect size, and independent cohorts and attempts to evaluate prospectively defined performance in a held-out cohort. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- Combination-Therapy Hypotheses: Mechanism Before Matrix
Treat Combination-Therapy Hypotheses as a ranking problem rather than a request for certainty. Define the decision about which combination has a plausible, discriminating rationale worth testing, assemble pathway complementarity, resistance mechanisms, exposure, toxicity, schedule, interaction models, and alternatives, and test whether the preferred route still leads after you predict a mechanistic rescue or resistance pattern unique to the combination. The recommendation remains bounded by the evidence and accountable specialist validation.
- Disease-Model Selection as a Scientific Decision
Disease-Model Selection as a Scientific Decision can shorten the search only by eliminating weak directions early. Start with which model is fit for the mechanism and decision being tested; compare mechanisms against construct validity, predictive validity, species or system differences, endpoints, heterogeneity, and feasibility; and try to break the ranking with this challenge: identify a known clinical or human-biology feature the model should reproduce. A negative result is valuable when it prevents the wrong validation cycle.
- Map the Translational Gap Before Advancing a Drug Program
For Map the Translational Gap Before Advancing a Drug Program, speed comes from a precise decision and a fast falsifier. State which unsupported bridge connects early evidence to the intended human outcome, evaluate competing routes with target engagement, tissue exposure, model relevance, biomarkers, effect size, safety, and patient heterogeneity, and attempt to test the weakest bridge with the most human-relevant available evidence. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- Target Competitive-Landscape Analysis as Evidence, Not Decoration
For Target Competitive-Landscape Analysis as Evidence, Not Decoration, the bounded choice is whether a target thesis is differentiated scientifically and developmentally. Compare at least three live alternatives using active programs, failures, modalities, indications, trial outcomes, patents, and mechanism differences, then run the cheapest ranking-reversal test: explain why prior failures do or do not apply to the current thesis. The defensible output is pursue, reframe, or stop—not final validation.
- How to Read Clinical-Trial Records for Discovery Decisions
Use How to Read Clinical-Trial Records for Discovery Decisions to decide which trial evidence informs an upstream target or mechanism decision before the next expensive commitment. Build the comparison around design, population, endpoints, status, results posting, intervention, comparator, and termination reasons and ask what would overturn the preferred route; the earliest useful challenge is: compare registry entries with publications and regulatory sources for consistency. Stop at a provisional decision and preserve the remaining validation boundary.
- Protein-Structure Evidence in Target and Candidate Decisions
The practical question behind Protein-Structure Evidence in Target and Candidate Decisions is which structural observation is decision-relevant rather than merely visually persuasive. Rank credible alternatives with experimental method, resolution, conformational state, construct, ligands, predicted regions, and dynamics, expose the strongest counterargument, and challenge the leader by trying to test whether the claimed interaction persists across plausible conformations and structures. A useful answer changes the next allocation decision without pretending computation is final proof.
- The Evidence Ceiling in Computational Drug Discovery
The Evidence Ceiling in Computational Drug Discovery becomes decision-useful when the team states what a computational result can responsibly claim before experiments, not when it collects another undirected summary. Use benchmarking, leakage, domain applicability, uncertainty, prospective prediction, and biological context to compare mechanisms and run this early falsifier: evaluate on a truly held-out or prospective case with predeclared criteria. Continue only if the ranking survives.